2-Methyl-6-(Phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active MGlu5 receptor antagonist: F. Gasparini, et al.; Neuropharmacology 38, 1493 (1999) Abstract Pharmacological agents acting at subtypes of metabotropic glutamate receptors: D.D. Schoepp, et al.; Neuropharmacology 38, 1431 (1999) Abstract Antagonism of the mGlu5 agonist 2-chloro-5-hydroxyphenylglycine by the novel selective mGlu5 antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) in the thalamus: T.E. Salt, et al.; Br. J. Pharmacol. 127, 1057 (1999) Abstract Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective: V. Bruno, et al.; Neuropharmacology 39, 2223 (2000) Abstract Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893): A.G. Chapman, et al.; Neuropharmacology 39, 1567 (2000) Abstract Methylphenylethynylpyridine (MPEP) Novartis: F. Micheli; Curr. Opin. Investig. Drugs 1, 355 (2000) Abstract Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist: E. Tatarczynska, et al.; Br. J. Pharmacol. 132, 1423 (2001) Abstract; Full Text Glutamate release inhibiting properties of the novel mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP): complementary in vitro and in vivo evidence: L.S. Thomas, et al.; Neuropharmacology 41, 523 (2001) Abstract Evidence that the metabotropic glutamate receptor 5 antagonist MPEP may act as an inhibitor of the norepinephrine transporter in vitro and in vivo: C.A. Heidbreder, et al.; Synapse 50, 269 (2003) Abstract In the amygdala anxiolytic action of mGlu5 receptors antagonist MPEP involves neuropeptide Y but not GABAA signaling: J.M. Wieronska, et al.; Neuropsychopharmacology 29, 514 (2004) Abstract; Full Text Chronic treatment with the mGlu5R antagonist MPEP reduces the functional effects of the mGlu5R agonist CHPG in the striatum of 6-hydroxydopamine-lesioned rats: possible relevance to the effects of mGlu5R blockade in Parkinson’s disease: M.R. Domenici, et al.; J. Neurosci. Res. 80, 646 (2005) Abstract Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats: M. Pietraszek, et al.; Eur. J. Pharmacol. 514, 25 (2005) Abstract
|